Implantable cardioverter defibrillators have been shown to provide similar survival benefits for patients who have left ventricular dysfunction due to ischemic heart disease and for subsets of patients who have nonischemic cardiomyopathy. Findings in this study extend these observations by showing that patients who have ischemic or nonischemic heart disease and receive implantable cardioverter defibrillators not only have comparable mortality rates but also similar tachyarrhythmia frequencies during follow-up; further, mortality and tachyarrhythmia outcomes are independent of initial arrhythmia indication.
Bibliographical noteFunding Information:
Dr. Ermis was supported in part by the Midwest Arrhythmia Research Foundation, Edina, Minnesota. Grant funding was received from the Midwest Arrhythmia Research Foundation, Edina, Minnesota, and from Medtronic Inc., Minneapolis, Minnesota. Dr. Lin was supported in part by an LRP grant from the National Institutes of Health, Bethesda, Maryland.